Edition:
United States

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

6.36USD
16 Nov 2018
Change (% chg)

$-0.05 (-0.78%)
Prev Close
$6.41
Open
$6.38
Day's High
$6.71
Day's Low
$6.20
Volume
3,614
Avg. Vol
3,261
52-wk High
$7.90
52-wk Low
$5.11

Latest Key Developments (Source: Significant Developments)

Cumberland Pharmaceuticals Q3 Adjusted Loss Per Share $0.05
Tuesday, 13 Nov 2018 04:05pm EST 

Cumberland Pharmaceuticals Inc ::CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.05.Q3 REVENUE $8.5 MILLION VERSUS $11.2 MILLION.Q3 LOSS PER SHARE $0.11.  Full Article

Cumberland Pharmaceuticals to acquire Vibativ
Tuesday, 6 Nov 2018 08:30am EST 

Nov 6 (Reuters) - Cumberland Pharmaceuticals Inc ::CUMBERLAND PHARMACEUTICALS TO ACQUIRE VIBATIV.CUMBERLAND PHARMACEUTICALS INC - FINANCIAL TERMS INCLUDE A $20 MILLION PAYMENT TO THERAVANCE BIOPHARMA UPON CLOSING.CUMBERLAND PHARMACEUTICALS INC - FINANCIAL TERMS INCLUDE A $20 MILLION PAYMENT TO THERAVANCE BIOPHARMA UPON CLOSING.CUMBERLAND PHARMACEUTICALS INC - CUMBERLAND EXPECTS THAT ADDITION OF VIBATIV WILL BE ACCRETIVE TO COMPANY'S EARNINGS..CUMBERLAND PHARMACEUTICALS INC - TERMS ALSO INCLUDE A $5 MILLION ADDITIONAL PAYMENT IN EARLY 2019.CUMBERLAND PHARMACEUTICALS - TERMS HAVE $5 MILLION ADDITIONAL PAYMENT IN EARLY 2019, AND TIERED ROYALTIES OF UP TO 20% ON FUTURE US NET PRODUCT SALES.CUMBERLAND PHARMACEUTICALS INC - ENTERED DEFINITIVE AGREEMENT TO ACQUIRE VIBATIV FROM THERAVANCE BIOPHARMA.  Full Article

Cumberland Pharmaceuticals Inc - Submitted An Amendment To Application For Approval Of Caldolor Injection Product Containing Additional Data
Monday, 1 Oct 2018 05:43pm EDT 

Oct 1 (Reuters) - Cumberland Pharmaceuticals Inc ::CUMBERLAND PHARMACEUTICALS INC - SUBMITTED AN AMENDMENT TO APPLICATION FOR APPROVAL OF CALDOLOR INJECTION PRODUCT CONTAINING ADDITIONAL DATA.CUMBERLAND PHARMACEUTICALS INC - NOW AWAIT FDA'S RESPONSE AND APPROVAL DECISION EXPECTED BY LATE JANUARY 2019 - SEC FILING.CUMBERLAND PHARMACEUTICALS - ON AUG 2, RECEIVED A CRL FROM FDA OUTLINING ADDITIONAL INFORMATION NEEDED FOR APPLICATION'S APPROVAL OF CALDOLOR.  Full Article

Cumberland Pharmaceuticals- Entered Agreement With Gastro-Entero Logic To Acquire Assets Associated With Omeclamox((Reg))-Pak
Friday, 16 Mar 2018 05:27pm EDT 

March 16 (Reuters) - Cumberland Pharmaceuticals Inc ::CUMBERLAND PHARMACEUTICALS-ON MARCH 13, ENTERED AGREEMENT WITH GASTRO-ENTERO LOGIC, LLC TO ACQUIRE ASSETS ASSOCIATED WITH OMECLAMOX((REG))-PAK.CUMBERLAND - HAS REMOVED OBLIGATION TO PROVIDE GEL WITH ROYALTY PAYMENTS BASED ON GROSS MARGIN AS WELL AS FEES FOR OVERSEEING PRODUCT'S MANUFACTURING.CUMBERLAND PHARMACEUTICALS SAYS IS NOW RESPONSIBLE FOR MAINTAINING FDA APPROVAL AND FOR OVERSEEING OMECLAMOX((REG))-PAK 'S PACKAGING - SEC FILING.  Full Article

Cumberland Pharma Q4 Adjusted Earnings Per Share $0.03
Tuesday, 6 Mar 2018 04:05pm EST 

March 6 (Reuters) - Cumberland Pharmaceuticals Inc ::CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017.Q4 ADJUSTED EARNINGS PER SHARE $0.03.Q4 REVENUE ROSE 28 PERCENT TO $11.6 MILLION.  Full Article

Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million
Tuesday, 7 Nov 2017 05:40pm EST 

Nov 7 (Reuters) - Cumberland Pharmaceuticals Inc ::Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million .  Full Article

Cumberland Pharmaceutical reports Q3 loss per share $0.05
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceutical reports 27% revenue growth in the third quarter.Q3 adjusted earnings per share $0.01.Q3 revenue rose 27 percent to $11.2 million.Q3 loss per share $0.05.  Full Article

Cumberland Pharmaceuticals launches promotion of Totect in U.S. for emergency oncology intervention
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Clinigen Group Plc :Cumberland Pharmaceuticals launches promotion of Totect® in the U.S. for emergency oncology intervention.Cumberland Pharmaceuticals Inc - ‍announced promotional launch of totect (dexrazoxane hydrochloride), in U.S.​.  Full Article

Cumberland Pharmaceuticals Q2 adjusted loss per share $0.05
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceutical reports double digit revenue growth for the fourth consecutive quarter.Q2 adjusted loss per share $0.05.Q2 loss per share $0.32.Q2 revenue rose 17 percent to $8.7 million.Cumberland Pharmaceuticals - ‍new co-promotion agreement for Kristalose added; at June 30, had $49.0 million in cash and marketable securities, including approximately $34.6 million in cash and equivalents​.  Full Article

Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support
Monday, 31 Jul 2017 08:15am EDT 

July 31 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support.Cumberland Pharmaceuticals Inc - under terms of agreement, Cumberland is managing all marketing, promotion, and distribution of Totect in U.S..Cumberland Pharmaceuticals Inc - will begin distributing dexrazoxane, sold under brand name Totect, to U.S. wholesalers.  Full Article